NeuroSense Therapeutics
Herzliya
About NeuroSense Therapeutics
NeuroSense Therapeutics Ltd., is a clinical-stage biotechnology company, dedicated to the discovery and development of treatments for debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company's preclinical pipeline includes: (1) StabiliC for the treatment of Parkinson's disease and (2) CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $15.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2025)
- Ticker: nasdaq:NRSN
- Website: neurosense-tx.com
- Phone: +972-9-9531142
Industries & Categories
Biotechnology, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/neurosense-therapeutics-75407 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.